RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
Balance beginning | $ 12,380,973 | $ 12,501,095 | $ (15,158,968) | $ (8,387,900) | $ 1,370,983 | $ 8,153,244 | $ 17,912,049 | $ 23,127,139 | $ 29,063,131 | $ 8,153,244 | $ 29,063,131 | $ (15,158,968) | $ 8,153,244 | $ 29,063,131 | $ 8,153,244 | $ 29,063,131 |
Balance beginning Series D preferred stock | $ 1,382,023 | 1,382,023 | 1,382,023 | $ 1,382,023 | 1,382,023 | 1,382,023 | ||||||||||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | ||||||||||||||
Stock-based compensation (Note7) | 1,534,054 | 799,249 | $ 454,363 | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | $ 1,452,964 | |||||
Exercise of warrants into common shares | 2,298,143 | 649,250 | 2,467,222 | |||||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | $ (3,239,112) | ||||||||||||||
Stock awards (Note 7) (in shares) | 1,617,000 | 440,250 | ||||||||||||||
NET LOSS | 14,664,719 | 919,371 | 26,641,983 | 17,520,378 | 10,178,640 | 7,190,470 | 7,511,322 | 5,635,043 | 6,239,797 | 17,369,110 | 11,874,840 | $ 42,226,073 | 34,889,488 | 19,386,162 | $ 42,770,610 | $ 31,792,618 |
Issuance of common stock and pre-funded warrants net of issuance costs | 9,429,767 | |||||||||||||||
Balance ending Series D preferred stock | 19,202,023 | 1,382,023 | 19,202,023 | 1,382,023 | $ 1,382,023 | 1,382,023 | ||||||||||
Balance ending Series D preferred stock (in shares) | 111.11 | |||||||||||||||
Balance ending | 15,164,940 | 12,380,973 | 12,501,095 | (28,000,262) | (8,387,900) | 1,370,983 | 10,768,486 | 17,912,049 | 23,127,139 | (8,387,900) | 17,912,049 | 15,164,940 | (28,000,262) | 10,768,486 | $ (15,158,968) | 8,153,244 |
As previously reported | ||||||||||||||||
Balance beginning | (1,356,047) | (467,004) | 7,334,461 | 15,507,519 | 20,194,072 | 27,209,162 | 33,045,154 | 15,507,519 | 33,045,154 | (1,356,047) | 15,507,519 | 33,045,154 | 15,507,519 | 33,045,154 | ||
Stock-based compensation (Note7) | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||||||
Exercise of warrants into common shares | 348,638 | 789,642 | ||||||||||||||
NET LOSS | 13,732,350 | 8,221,222 | 8,581,267 | 7,811,322 | 7,435,043 | 6,139,797 | 16,802,489 | 13,574,840 | 30,534,839 | 21,386,162 | 37,983,496 | 28,601,254 | ||||
Issuance of common stock and pre-funded warrants net of issuance costs | 17,920,000 | 9,610,655 | ||||||||||||||
Balance ending Series D preferred stock | 17,920,000 | 17,920,000 | ||||||||||||||
Balance ending | (13,352,838) | (467,004) | 7,334,461 | 12,750,509 | 20,194,072 | 27,209,162 | (467,004) | 20,194,072 | (13,352,838) | 12,750,509 | (1,356,047) | 15,507,519 | ||||
Restatement adjustments | ||||||||||||||||
Balance beginning | (13,802,921) | (7,920,896) | (5,963,478) | (7,354,275) | (2,282,023) | (4,082,023) | (3,982,023) | (7,354,275) | (3,982,023) | (13,802,921) | (7,354,275) | (3,982,023) | (7,354,275) | (3,982,023) | ||
Balance beginning Series D preferred stock | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||||||
Exercise of warrants into common shares | 300,612 | 1,677,580 | ||||||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | (3,239,112) | (7,005,493) | |||||||||||||
NET LOSS | 3,788,028 | 1,957,418 | (1,390,797) | (300,000) | (1,800,000) | 100,000 | 566,621 | (1,700,000) | 4,354,649 | (2,000,000) | 4,787,114 | 3,191,364 | ||||
Balance ending Series D preferred stock | 1,282,023 | 1,382,023 | 1,282,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||||||
Balance ending | (14,647,424) | (7,920,896) | (5,963,478) | (1,982,023) | (2,282,023) | (4,082,023) | (7,920,896) | (2,282,023) | (14,647,424) | (1,982,023) | (13,802,921) | (7,354,275) | ||||
Series D preferred stock | ||||||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 |
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 |
Balance ending Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 19,202,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 19,202,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 |
Balance ending Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 1,336.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 1,336.11 | 111.11 | 111.11 | 111.11 |
Series D preferred stock | Restatement adjustments | ||||||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||||
Balance ending Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | |||||||||
Balance ending Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | |||||||||
Series E-1 preferred stock | ||||||||||||||||
Shares issued | 1,225 | |||||||||||||||
Fair value of the warrants allocated to preferred stock | $ 17,820,000 | |||||||||||||||
Balance ending Series D preferred stock (in shares) | 1,225 | 1,225 | ||||||||||||||
Series E-2 Preferred Stock | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | $ 17,820,000 | |||||||||||||||
Series E-2 Preferred Stock | Restatement adjustments | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | (100,000) | |||||||||||||||
Preferred Stock | ||||||||||||||||
Balance beginning | $ 7,843,603 | $ 17,067,715 | $ 4,677,632 | $ 4,677,632 | ||||||||||||
Balance beginning (in shares) | 440 | 867.5 | 319.76 | 319.76 | ||||||||||||
Conversion of preferred stock to common stock | $ (13,142,368) | |||||||||||||||
Conversion of preferred stock to common stock (in shares) | (905.24) | |||||||||||||||
Balance ending | $ 13,615,544 | $ 7,843,603 | $ 17,067,715 | $ 13,615,544 | $ 4,677,632 | |||||||||||
Balance ending (in shares) | 1,066.1 | 440 | 867.5 | 1,066.1 | 319.76 | |||||||||||
Preferred Stock | As previously reported | ||||||||||||||||
Balance beginning | $ 6,059,655 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 6,059,655 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||
Balance beginning (in shares) | 430.87 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 430.87 | 111.11 | 111.11 | 111.11 | 111.11 | ||
Conversion of preferred stock to common stock | $ (13,242,368) | |||||||||||||||
Conversion of preferred stock to common stock (in shares) | (905.24) | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 17,920,000 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225 | |||||||||||||||
Balance ending | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 6,059,655 | $ 1,382,023 | ||||
Balance ending (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 430.87 | 111.11 | ||||
Preferred Stock | Restatement adjustments | ||||||||||||||||
Balance beginning | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | ||
Balance beginning (in shares) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | ||
Conversion of warrants into common shares | $ 100,000 | |||||||||||||||
Balance ending | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | ||||
Balance ending (in shares) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | ||||
Preferred Stock | Series E-1 preferred stock | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | $ 17,820,000 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225 | |||||||||||||||
Preferred Stock | Series E-1 preferred stock | As previously reported | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | $ 17,920,000 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225 | |||||||||||||||
Preferred Stock | Series E-1 preferred stock | Restatement adjustments | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | $ (100,000) | |||||||||||||||
Preferred Stock | Series E-2 Preferred Stock | ||||||||||||||||
Conversion of preferred stock to common stock | $ (1,285,851) | $ (1,203,346) | ||||||||||||||
Conversion of preferred stock to common stock (in shares) | (87.9) | 82.26 | ||||||||||||||
Shares issued | 1,225 | |||||||||||||||
Fair value of the warrants allocated to preferred stock | $ 17,820,000 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225 | |||||||||||||||
Preferred Stock | Series E-2 Preferred Stock | Restatement adjustments | ||||||||||||||||
Fair value of the warrants allocated to preferred stock | $ (100,000) | |||||||||||||||
Common Stock | ||||||||||||||||
Balance beginning | $ 358 | $ 332 | $ 207 | $ 97 | $ 97 | $ 94 | $ 61 | $ 61 | $ 61 | $ 94 | $ 61 | $ 207 | $ 94 | $ 61 | $ 94 | $ 61 |
Balance beginning (in shares) | 35,848,924 | 33,164,466 | 20,744,110 | 9,740,507 | 9,740,507 | 9,385,272 | 6,110,122 | 6,110,124 | 6,110,125 | 9,385,272 | 6,110,125 | 20,744,110 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 |
Exercise of warrants into common shares | $ 5 | $ 2 | $ 12 | |||||||||||||
Exercise of warrants into common shares (in shares) | 547,177 | 177,877 | 1,197,622 | |||||||||||||
Conversion of preferred stock to common stock | $ 99 | |||||||||||||||
Conversion of preferred stock to common stock (in shares) | 9,947,684 | |||||||||||||||
Stock awards (Note 7) | $ 2 | |||||||||||||||
Stock awards (Note 7) (in shares) | 213,532 | |||||||||||||||
Retired shares (in shares) | (8) | (4) | (2) | (1) | (6) | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 33 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 3,275,153 | |||||||||||||||
Balance ending | $ 406 | $ 358 | $ 332 | $ 99 | $ 97 | $ 97 | $ 61 | $ 61 | $ 61 | $ 97 | $ 61 | $ 406 | $ 99 | $ 61 | $ 207 | $ 94 |
Balance ending (in shares) | 40,566,534 | 35,848,924 | 33,164,466 | 9,918,384 | 9,740,507 | 9,740,507 | 6,110,118 | 6,110,122 | 6,110,124 | 9,740,507 | 6,110,122 | 40,566,534 | 9,918,384 | 6,110,118 | 20,744,110 | 9,385,272 |
Common Stock | As previously reported | ||||||||||||||||
Balance beginning | $ 207 | $ 97 | $ 97 | $ 94 | $ 61 | $ 61 | $ 61 | $ 94 | $ 61 | $ 207 | $ 94 | $ 61 | $ 94 | $ 61 | ||
Balance beginning (in shares) | 20,744,110 | 9,740,507 | 9,740,507 | 9,385,272 | 6,110,122 | 6,110,124 | 6,110,125 | 9,385,272 | 6,110,125 | 20,744,110 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 | ||
Exercise of warrants into common shares | $ 2 | $ 12 | ||||||||||||||
Exercise of warrants into common shares (in shares) | 177,877 | 1,197,622 | ||||||||||||||
Conversion of preferred stock to common stock | $ 99 | |||||||||||||||
Conversion of preferred stock to common stock (in shares) | 9,947,684 | |||||||||||||||
Stock awards (Note 7) | $ 2 | |||||||||||||||
Stock awards (Note 7) (in shares) | 213,532 | |||||||||||||||
Retired shares (in shares) | (4) | (2) | (1) | (6) | ||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 33 | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 3,275,153 | |||||||||||||||
Balance ending | $ 99 | $ 97 | $ 97 | $ 61 | $ 61 | $ 61 | $ 97 | $ 61 | $ 99 | $ 61 | $ 207 | $ 94 | ||||
Balance ending (in shares) | 9,918,384 | 9,740,507 | 9,740,507 | 6,110,118 | 6,110,122 | 6,110,124 | 9,740,507 | 6,110,122 | 9,918,384 | 6,110,118 | 20,744,110 | 9,385,272 | ||||
Common Stock | Series E-2 Preferred Stock | ||||||||||||||||
Conversion of preferred stock to common stock | $ 10 | $ 9 | ||||||||||||||
Conversion of preferred stock to common stock (in shares) | 965,934 | 903,956 | ||||||||||||||
Additional Paid-In Capital | ||||||||||||||||
Balance beginning | $ 234,859,383 | $ 224,836,048 | $ 182,924,210 | $ 168,971,520 | $ 168,551,763 | $ 168,143,557 | $ 157,984,617 | $ 157,564,664 | $ 157,260,859 | $ 168,143,557 | $ 157,260,859 | $ 182,924,210 | $ 168,143,557 | $ 157,260,859 | $ 168,143,557 | $ 157,260,859 |
Stock-based compensation (Note7) | 1,534,054 | 799,249 | 454,363 | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | |||||
Exercise of warrants into common shares | 2,298,138 | $ 649,248 | 2,467,210 | |||||||||||||
Exercise of warrants into common shares (in shares) | 649,248 | |||||||||||||||
Conversion of preferred stock to common stock | 13,142,269 | |||||||||||||||
Reclassification of pre-funded warrants to liability | $ (3,239,112) | (3,239,112) | ||||||||||||||
Stock awards (Note 7) | (2) | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 9,429,734 | |||||||||||||||
Balance ending | 246,536,080 | 234,859,383 | 224,836,048 | 166,879,534 | 168,971,520 | 168,551,763 | 158,352,376 | 157,984,617 | 157,564,664 | 168,971,520 | 157,984,617 | 246,536,080 | 166,879,534 | 158,352,376 | 182,924,210 | 168,143,557 |
Additional Paid-In Capital | As previously reported | ||||||||||||||||
Balance beginning | 210,066,630 | 194,452,408 | 194,032,651 | 193,624,445 | 183,284,617 | 182,864,664 | 182,560,859 | 193,624,445 | 182,560,859 | 210,066,630 | 193,624,445 | 182,560,859 | 193,624,445 | 182,560,859 | ||
Stock-based compensation (Note7) | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||||||
Exercise of warrants into common shares | 348,636 | 789,630 | ||||||||||||||
Conversion of preferred stock to common stock | 13,242,269 | |||||||||||||||
Stock awards (Note 7) | (2) | |||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 9,610,622 | |||||||||||||||
Balance ending | 195,298,922 | 194,452,408 | 194,032,651 | 183,652,376 | 183,284,617 | 182,864,664 | 194,452,408 | 183,284,617 | 195,298,922 | 183,652,376 | 210,066,630 | 193,624,445 | ||||
Additional Paid-In Capital | Restatement adjustments | ||||||||||||||||
Balance beginning | (27,142,420) | (25,480,888) | (25,480,888) | (25,480,888) | (25,300,000) | (25,300,000) | (25,300,000) | (25,480,888) | (25,300,000) | (27,142,420) | (25,480,888) | (25,300,000) | (25,480,888) | (25,300,000) | ||
Exercise of warrants into common shares | 300,612 | 1,677,580 | ||||||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | (3,239,112) | (7,005,493) | |||||||||||||
Conversion of warrants into common shares | (100,000) | |||||||||||||||
Balance ending | (28,419,388) | (25,480,888) | (25,480,888) | (25,300,000) | (25,300,000) | (25,300,000) | (25,480,888) | (25,300,000) | (28,419,388) | (25,300,000) | (27,142,420) | (25,480,888) | ||||
Additional Paid-In Capital | Series E-2 Preferred Stock | ||||||||||||||||
Conversion of preferred stock to common stock | 1,285,841 | 1,203,337 | ||||||||||||||
Accumulated Deficit | ||||||||||||||||
Balance beginning | (230,322,371) | (229,403,000) | (202,761,017) | (177,359,517) | (167,180,877) | (159,990,407) | (140,072,629) | (134,437,586) | (128,197,789) | (159,990,407) | (128,197,789) | (202,761,017) | (159,990,407) | (128,197,789) | (159,990,407) | (128,197,789) |
NET LOSS | 14,664,719 | 919,371 | 26,641,983 | 17,520,378 | 10,178,640 | 7,190,470 | 7,511,322 | 5,635,043 | 6,239,797 | 42,770,610 | 31,792,618 | |||||
Balance ending | $ (244,987,090) | $ (230,322,371) | (229,403,000) | (194,879,895) | (177,359,517) | (167,180,877) | (147,583,951) | (140,072,629) | (134,437,586) | (177,359,517) | (140,072,629) | (244,987,090) | (194,879,895) | (147,583,951) | (202,761,017) | (159,990,407) |
Accumulated Deficit | As previously reported | ||||||||||||||||
Balance beginning | (217,482,539) | (196,301,532) | (188,080,310) | (179,499,043) | (164,472,629) | (157,037,586) | (150,897,789) | (179,499,043) | (150,897,789) | (217,482,539) | (179,499,043) | (150,897,789) | (179,499,043) | (150,897,789) | ||
NET LOSS | 13,732,350 | 8,221,222 | 8,581,267 | 7,811,322 | 7,435,043 | 6,139,797 | 37,983,496 | 28,601,254 | ||||||||
Balance ending | (210,033,882) | (196,301,532) | (188,080,310) | (172,283,951) | (164,472,629) | (157,037,586) | (196,301,532) | (164,472,629) | (210,033,882) | (172,283,951) | (217,482,539) | (179,499,043) | ||||
Accumulated Deficit | Restatement adjustments | ||||||||||||||||
Balance beginning | 14,721,522 | 18,942,015 | 20,899,433 | 19,508,636 | 24,400,000 | 22,600,000 | 22,700,000 | 19,508,636 | 22,700,000 | $ 14,721,522 | 19,508,636 | 22,700,000 | 19,508,636 | 22,700,000 | ||
NET LOSS | 3,788,028 | 1,957,418 | (1,390,797) | (300,000) | (1,800,000) | 100,000 | 4,787,114 | 3,191,364 | ||||||||
Balance ending | $ 15,153,987 | $ 18,942,015 | 20,899,433 | $ 24,700,000 | $ 24,400,000 | $ 22,600,000 | $ 18,942,015 | $ 24,400,000 | $ 15,153,987 | $ 24,700,000 | $ 14,721,522 | 19,508,636 | ||||
Pre-funded warrants | ||||||||||||||||
Conversion of preferred stock to common stock | 3,972,540 | 3 | ||||||||||||||
Conversion of warrants into common shares | 3 | |||||||||||||||
Pre-funded warrants | As previously reported | ||||||||||||||||
Conversion of warrants into common shares | 3 | |||||||||||||||
Pre-funded warrants | Common Stock | ||||||||||||||||
Conversion of preferred stock to common stock | $ 11 | $ 3 | ||||||||||||||
Conversion of preferred stock to common stock (in shares) | 1,079,132 | 355,235 | ||||||||||||||
Conversion of warrants into common shares | $ 3 | |||||||||||||||
Conversion of warrants into common shares (in shares) | 355,235 | |||||||||||||||
Pre-funded warrants | Common Stock | As previously reported | ||||||||||||||||
Conversion of warrants into common shares | $ 3 | |||||||||||||||
Conversion of warrants into common shares (in shares) | 355,235 | |||||||||||||||
Pre-funded warrants | Additional Paid-In Capital | ||||||||||||||||
Conversion of preferred stock to common stock | $ 3,972,529 | |||||||||||||||
Warrants | Restatement adjustments | ||||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 6,824,605 | |||||||||||||||
Warrants | Additional Paid-In Capital | Restatement adjustments | ||||||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 6,824,605 |